Query: Systematic analysis of glaucoma-associated biomarkers, including matrix metalloproteinases, fibronectin, myocilin, alpha-SMA, oxidative stress markers like 4-HNE, and inflammatory cytokines in aqueous humor and trabecular meshwork cells, to define robust mechanistic endpoints and predictive therapeutic targets for cellular assay development

Glaucoma represents a multifactorial neurodegenerative disease in which intraocular pressure elevation is intricately linked to cellular and extracellular alterations in the trabecular meshwork (TM) and aqueous humor. A systematic analysis of biomarkers—including matrix metalloproteinases (MMPs), fibronectin, myocilin, alpha‐smooth muscle actin (alpha-SMA), oxidative stress markers like 4-hydroxynonenal (4-HNE), and inflammatory cytokines—reveals that these molecules reflect tissue remodeling, oxidative injury, fibrotic transition, and inflammation, all of which contribute to TM dysfunction and impaired aqueous humor outflow (Clinical Trials Search: glaucoma).

Matrix metalloproteinases, particularly MMP-2, MMP-9, and MMP-13, are zinc-dependent endopeptidases responsible for orchestrating extracellular matrix (ECM) degradation and remodeling. In the TM, altered MMP activity correlates with changes in aqueous humor outflow resistance; for example, elevated MMP-9 levels have been associated with retinal ganglion cell apoptosis and neuronal degeneration, providing a functional link between ECM turnover and glaucomatous progression (cerbulescu2025theimpactof pages 2-3, dammak2023newbiomarkercombination pages 1-2). Moreover, such alterations in MMP levels often go hand in hand with an increased deposition of fibronectin, a critical ECM glycoprotein that modulates cell-matrix adhesion and mechanical properties of the TM. The dysregulation of fibronectin can increase tissue stiffness and further impede aqueous humor drainage (cueto2021candidateglaucomabiomarkers pages 7-8).

Myocilin, a protein encoded by the MYOC gene, is perhaps one of the most extensively studied molecules in glaucoma research. Mutations in the MYOC gene frequently result in protein accumulation within TM cells, leading to cellular stress and disruption of normal outflow dynamics. This makes myocilin not only a marker of genetic predisposition but also a mechanistic endpoint for evaluating cellular health in therapeutic assays (NCT06465537). Concurrently, alpha-SMA is expressed during the phenotypic transition of TM cells towards a more contractile and fibrotic state. Its upregulation highlights cytoskeletal reorganization and fibrosis, indicative of TM tissue remodeling that further exacerbates intraocular pressure (cueto2021candidateglaucomabiomarkers pages 7-8, dammak2024…relacionadoscon pages 83-88).

Oxidative stress plays a central role in glaucomatous pathology, and 4-HNE is a particularly relevant biomarker of lipid peroxidation-induced oxidative damage. Elevated levels of 4-HNE in the aqueous humor and TM not only serve as indicators of reactive oxygen species (ROS) activity but also signify the ongoing cellular damage that contributes to TM dysfunction and subsequent visual field loss (dammak2024…relacionadoscon pages 83-88).

Inflammatory cytokines further complicate the glaucomatous milieu. Elevated cytokines in the aqueous humor, including TNF-α, TGF-β, IL-12, and others, contribute to a chronic inflammatory state that promotes ECM remodeling, cellular apoptosis, and further activation of MMPs. This interdependent network of cytokines and proteases establishes feedback loops that exacerbate tissue damage, positioning inflammatory mediators as both biomarkers and therapeutic targets (NCT06243497, cueto2021candidateglaucomabiomarkers pages 7-8).

The measurement of these biomarkers in both aqueous humor and TM cells can thus serve as robust mechanistic endpoints for cellular assay development. Using in vitro models derived from patient biopsies or primary cell cultures, researchers are now able to quantify these markers and assess their modulation in response to therapeutic interventions. The quantitative assessment provides a predictive framework: changes in MMP activity, fibronectin deposition, myocilin aggregation, alpha-SMA expression, levels of 4-HNE, and inflammatory cytokine profiles can be linked directly to improved TM functionality and reduced intraocular pressure (NCT02151318, NCT06190119).

Ultimately, these biomarkers provide a multi-dimensional insight into the pathophysiology of glaucoma and create a solid foundation for the development of targeted cellular assays. By exploring modifications in ECM remodeling, oxidative stress, inflammation, and fibrosis, researchers can efficiently screen novel therapeutic agents that may restore TM homeostasis and ameliorate glaucomatous damage. This integrative biomarker strategy not only enhances our understanding of glaucoma progression but also advances predictive therapeutic approaches, improving both preclinical assay development and clinical outcomes (NCT02638181, NCT06243497).

References:
1. (cerbulescu2025theimpactof pages 2-3): Teodor Cerbulescu, Andrei Anghel, Diduţa Alina Brie, Flavia Medana Petraşcu, Mădălina Casiana Salavat, Adina Iuliana Ardelean, Ileana Ramona Barac, and Ovidiu Borugă. The impact of matrix metalloproteinases and their tissue inhibitors in patients with chronic glaucoma – a literature review. Romanian Journal of Morphology and Embryology, 65:557-565, Feb 2025. URL: https://doi.org/10.47162/rjme.65.4.01, doi:10.47162/rjme.65.4.01. This article has 1 citations and is from a peer-reviewed journal.

2. (cueto2021candidateglaucomabiomarkers pages 7-8): Andrés Fernández-Vega Cueto, Lydia Álvarez, Montserrat García, Ana Álvarez-Barrios, Enol Artime, Luis Fernández-Vega Cueto, Miguel Coca-Prados, and Héctor González-Iglesias. Candidate glaucoma biomarkers: from proteins to metabolites, and the pitfalls to clinical applications. Biology, 10:763, Aug 2021. URL: https://doi.org/10.3390/biology10080763, doi:10.3390/biology10080763. This article has 31 citations and is from a peer-reviewed journal.

3. (dammak2023newbiomarkercombination pages 1-2): Azza Dammak, Juan Sanchez Naves, Fernando Huete-Toral, and Gonzalo Carracedo. New biomarker combination related to oxidative stress and inflammation in primary open-angle glaucoma. Life, 13:1455, Jun 2023. URL: https://doi.org/10.3390/life13071455, doi:10.3390/life13071455. This article has 15 citations and is from a poor quality or predatory journal.

4. (NCT02638181): Lv Yingjuan. The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork. Lv Yingjuan. 2013. ClinicalTrials.gov Identifier: NCT02638181

5. (NCT06243497):  Comparison of Cytokines Profile in Aqueous Humor and Tear Before and After UCP Treatment. Zhongshan Ophthalmic Center, Sun Yat-sen University. 2024. ClinicalTrials.gov Identifier: NCT06243497

6. (NCT06465537):  CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation. Shanghai BDgene Co., Ltd.. 2024. ClinicalTrials.gov Identifier: NCT06465537

7. (dammak2024…relacionadoscon pages 83-88): A Dammak. … relacionados con el estrés oxidativo y la inflamación en el glaucoma: aplicaciones de combinación de biomarcadores para el diagnóstico del glaucoma. Unknown journal, 2024.

8. (NCT02151318):  Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies. University of South Florida. 2014. ClinicalTrials.gov Identifier: NCT02151318

9. (NCT06190119):  Comparison of Aqueous Humor Adipokines in Glaucoma Patients and Healthy Controls. Peking University. 2023. ClinicalTrials.gov Identifier: NCT06190119
